The receptor tyrosine kinase ErbB2 (HER2) is an important biomarker that is overexpressed in ~25% of all breast cancers, is a key drug target, and is a member of a biologically important family of tyrosine kinases. Here, ERBB2 is linked to breast carcinoma.